Effects of Glucagon Peptide-1 on Blood Pressure Variability in Diabetic Hypertensive Patients
10.3969/j.issn.0253-9896.2014.08.015
- VernacularTitle:胰高血糖素肽1对糖尿病伴高血压患者血压变异性的影响
- Author:
Shaoqing WANG
;
Li ZANG
;
Li WANG
;
Fang GAO
;
Ping FU
- Publication Type:Journal Article
- Keywords:
glucagon-like peptide 1;
diabetes mellitus,type 2;
hypertension;
blood pressure variability
- From:
Tianjin Medical Journal
2014;(8):790-792
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of glucagon peptide-1(GLP-1) in blood pressure variability (BPV) in diabetic hypertensive patients. Methods A total of 120 diabetic hypertensive patients were included in this study. GLP-1 was used for the treatment. The values of body mass index (BMI), fasting blood glucose, glycosylated hemoglobin, creatine and 24-hour ambulatory blood pressure (BP) monitoring were detected before and after treatment with GLP-1 for six months. The clinical indices were compared before and after treatment. Results The values of fasting blood glucose (mmol/L:7.12± 0.64 vs 9.19±2.78), glycosylated hemoglobin (%:7.00±0.14 vs 8.28±1.32) and BMI (kg/m2:19.30±3.24 vs 24.5±4.53 ) were de-creased to the normal level after GLP-1 treatment for six months (P<0.05). There were significant decrease in the 24-h sys-tolic BP (mmHg:135.02 ± 16.57 vs 139.52 ± 15.60), daytime systolic BP (mmHg:132.5 ± 14.6 vs 136.44 ± 14.24), 24-h systolic BP variability (mmHg:12.20 ± 1.44 vs 12.73 ± 1.66), daytime systolic BP variability (mmHg:11.11 ± 1.48 vs 11.74 ± 1.52 ), and daytime diastolic BP variability (mmHg:7.03±1.42 vs 7.43±1.45) after GLP-1 treatment for six months (P<0.05). Conclu-sion GLP-1 can decrease BPV in diabetic hypertensive patients.
